APA
Tripp C. S., Cuff C., Campbell A. L., Hendrickson B. A., Voss J., Melim T., Wu C., Cherniack A. D. & Kim K. (20171204). RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. : Advances in therapy.
Chicago
Tripp Catherine S, Cuff Carolyn, Campbell Andrew L, Hendrickson Barbara A, Voss Jeff, Melim Terry, Wu Chengbin, Cherniack Andrew D and Kim Kenneth. 20171204. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. : Advances in therapy.
Harvard
Tripp C. S., Cuff C., Campbell A. L., Hendrickson B. A., Voss J., Melim T., Wu C., Cherniack A. D. and Kim K. (20171204). RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. : Advances in therapy.
MLA
Tripp Catherine S, Cuff Carolyn, Campbell Andrew L, Hendrickson Barbara A, Voss Jeff, Melim Terry, Wu Chengbin, Cherniack Andrew D and Kim Kenneth. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. : Advances in therapy. 20171204.